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PLipid-Lowering Therapy
Secondary Prevention With Bezafibrate
Therapy for the Treatment of Dyslipidemia
An Extended Follow-Up of the BIP Trial
Ilan Goldenberg, MD,*† Michal Benderly, PHD,† Uri Goldbourt, PHD,†‡ for the BIP Study Group
Tel Hashomer and Tel Aviv, Israel
Objectives This study was designed to evaluate the long-term cardiovascular benefit of bezafibrate therapy in coronary
heart disease patients enrolled in the BIP (Bezafibrate Infarction Prevention) trial.
Background The BIP trial yielded a nonsignificant 7.3% reduction in the rate of major cardiac events after a mean follow-up
period of 6.2 years, possibly owing to an increasing unbalanced usage of nonstudy lipid-lowering drugs (LLDs)
during the course of the trial.
Methods The adjusted risk for the combined end point of cardiac death or nonfatal myocardial infarction during an ex-
tended mean 8.2-year follow-up period of the BIP trial was assessed in 3,090 patients allocated to the original
bezafibrate (n  1,548) and placebo (n  1,542) groups of the trial.
Results During the extended follow-up period, nonstudy LLDs were administered to a significantly greater proportion of
placebo-allocated patients (57%) than bezafibrate-allocated patients (53%; p  0.02). Interaction-term analysis
demonstrated that the benefit of bezafibrate therapy was pronounced (18% risk reduction; p  0.03) without or
before treatment with nonstudy LLDs initiated during follow-up and attenuated (hazard ratio 1.05; p  0.85)
after therapy with nonstudy LLDs initiated during the observation period. Consistent with these findings, treat-
ment with bezafibrate was shown to be associated with a significant 17% risk reduction (p  0.03) when study
patients were censored from the analysis upon initiation of therapy with nonstudy LLDs.
Conclusions The data demonstrate that bezafibrate therapy in the BIP trial was associated with significant long-term cardio-
vascular protection that was attenuated by an unbalanced usage of nonstudy LLDs during the course of the
trial. (J Am Coll Cardiol 2008;51:459–65) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.048w
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mhe BIP (Bezafibrate Infarction Prevention) trial was de-
igned to assess the effect of raising high-density lipoprotein
holesterol (HDL-C) and reducing triglycerides on cardiac
isk in patients with established coronary heart disease
CHD), who exhibited total serum cholesterol in the
normal or slightly elevated” range (1). During the course of
he study, HDL-C increased by 18% and triglycerides were
educed by 21% among patients treated with the study
edication. However, despite these substantial lipid-
odifying effects, bezafibrate therapy was associated with
nly a relatively small, statistically nonsignificant, 7.3%
eduction in the study’s combined primary end point (fatal
r nonfatal myocardial infarction [MI] or sudden cardiac
eath) (2). The difference in outcome in the BIP trial from
ther major randomized secondary prevention trials, in
rom the *Heart Institute and the †Neufeld Cardiac Research Institute, Sheba
edical Center, Tel Hashomer, Israel; and the ‡Division of Epidemiology and
reventive Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv,
srael.b
Manuscript received August 6, 2007; revised manuscript received September 10,
007, accepted September 17, 2007.hich fibrate therapy was associated with a more meaning-
ul reduction in the risk of major cardiac events (3,4), may
e attributed to patient selection or to increasing use of
onstudy lipid-lowering drugs (LLDs) among the placebo-
llocated patients during the study. These factors may have
ttenuated the observed benefit of bezafibrate during the
riginal course of the trial. Therefore, it is possible that a
ore pronounced benefit of the study medication may be
dentified after a longer period of observation and appro-
riate adjustment for nonstudy LLD use during follow-up.
We hypothesized that the lipid-modifying effects of
ezafibrate therapy during the original double-blind phase
f the BIP trial resulted in an additional reduction in
ardiovascular events during a longer-term observation.
ethods
he BIP trial. The BIP trial evaluated the effect of
ezafibrate versus placebo on major coronary events and
ortality in CHD patients. Details of the study design haveeen previously published (1,2). Briefly, 3,090 male and
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Bezafibrate Therapy for Dyslipidemia January 29, 2008:459–65female patients 45 to 74 years of
age with a history of MI and/or
angina and a lipid profile of serum
total cholesterol between 180 and
250 mg/dl, low-density lipopro-
tein cholesterol (LDL-C) 180
mg/dl (160 mg/dl for patients
50 years), HDL-C 45 mg/dl,
and triglycerides300 mg/dl were
randomized to bezafibrate 400
mg/day or placebo between May
1990 and January 1993 and fol-
lowed up over a mean period of
6.2 years (median 6.2 years; in-
erquartile range 5.3 to 6.8 years).
xtended follow-up phase. After discontinuation of the
tudy medication, patients were observed for coronary
vents for an additional period, bringing the total follow-up
ime in the current analysis to a mean of 8.2 years (median
.9 years; interquartile range 7.2 to 8.7 years). All cardiac
vents during the BIP trial and the extended follow-up
eriod were monitored, and causes of death were established
y the same independent committee of 3 experienced
ardiologists.
nd points. The primary end point of the present analysis
as the occurrence of cardiac death or nonfatal MI, which-
ver came first, during the total follow-up time (comprising
he original double-blind phase and the extended follow-up
hase). Secondary end points, for patients free of primary
nd point, included hospitalization for unstable angina,
ercutaneous transluminal coronary angioplasty, coronary
rtery bypass grafting, stroke, and death from any cause.
tatistical analysis. Baseline characteristics by treatment
roup were compared using the chi-square test for categoric
arameters and Student t test for continuous variables.
urvival curves were constructed by the Kaplan-Meier
ethod, and the significance of the variation between them
as assessed using a log-rank test.
To avoid possible bias created by the fact that a relatively
igh rate of nonstudy LLDs were administered to unequal
roportions of patients in the 2 treatment arms, we used 2
lternative statistical methods to determine the benefit of
ezafibrate therapy in patients who were treated solely with
he study medication or before initiation of nonstudy LLD
herapy during the course of the trial: 1) in the first method,
atients who were treated with nonstudy LLDs were
ensored from the analysis upon initiation of those thera-
ies; and 2) in the second method, multivariate models were
urther adjusted for time-dependent nonstudy LLD ther-
py, and the nonstudy LLD  bezafibrate interaction was
sed to identify the effect of the study medication before and
fter initiation of nonstudy lipid-lowering therapies.
Because significant baseline clinical differences existed
etween patients who were treated and untreated with
onstudy LLDs during follow-up, we included a propensity
Abbreviations
and Acronyms
AP  angina pectoris
BMI  body mass index
CHD  coronary heart
disease
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
LLD  lipid lowering drugs
MI  myocardial infarctioncore (5) for receiving LLDs in the proportional hazards aime-dependent models. The propensity score was calcu-
ated by running a saturated model based upon 25 baseline
linical and laboratory covariates thought to be associated
ith lipid-lowering therapy. To further validate our find-
ngs, all analyses that included a propensity score were
epeated using multivariate Cox proportional hazards re-
ression modeling. Adjusted Cox models included factors
hown to be significantly associated with outcome (age,
rior MI, history of diabetes mellitus, reported hyperten-
ion, smoking at the time of inclusion to the study, chronic
bstructive pulmonary disease, and angina pectoris [AP]
unctional class).
The benefit of bezafibrate therapy was also assessed
ithin prespecified risk groups (stratified by the presence or
ack of the following: New York Heart Association func-
ional class 2, AP functional class 2, history of MI,
riglycerides 200 mg/dl, history of diabetes mellitus,
DL-C 40 mg/dl, and body mass index [BMI] 27
g/m2). In these analyses, the prespecified covariates 
reatment interaction terms were included in the models
hat were assessed using the 2 alternative statistical ap-
roaches described. The statistical software used for the
nalyses was SAS version 8.12 (SAS Institute, Cary, North
arolina).
esults
he present study comprised patients included in the
riginal publication (2): 1,548 patients allocated to the
ezafibrate group and 1,542 patients allocated to the pla-
ebo group. Clinical characteristics, laboratory values, and
edical therapy were similar in the 2 treatment groups and
ere described in the original publication (2). Mainly,
early 80% of study patients had a history of MI, and 10%
ad treated diabetes mellitus. Beta-blockers were prescribed
o nearly 40% of study patients, calcium-channel blockers to
0%, and angiotensin-converting enzyme inhibitors to 12%.
onstudy LLDs during the double-blind phase and the
xtended follow-up. Nonstudy LLDs comprised mainly
tatins and were administered to an increasing number of
lacebo-allocated patients during the double-blind phase of the
rial, whereas after the BIP trial the rate of use of nonstudy
LDs increased substantially to more than 50% in both
reatment groups (Fig. 1, Table 1). Notably, before and after
linded drug allocation, all types of nonstudy LLDs were
dministered to a greater proportion of placebo-allocated
atients compared with patients allocated to bezafibrate
Table 1).
Patients in both treatment groups who received medical
herapy with nonstudy LLDs during follow-up exhibited
ignificant baseline clinical and laboratory differences from
atients who were not treated with these medications
uring follow-up (Table 2), including a younger age, higher
aseline serum levels of total cholesterol and LDL-C, and a
ower frequency of medical therapy with beta-blockers. In
ddition, nonstudy LLDs were administered to a signifi-
c
w
c
C
f
c
s
t
0
o
c
n
r
g
p
b
i
t
t
m
c
(
a
f
a
i
M
c
d
2
r
f
U
t
r
n
C
m
p
p
1
S
i
1
M
s
m
a
f
n
s
s
t
c
i
f
b
l
D
I
t
o
t
i
UL
*
t
461JACC Vol. 51, No. 4, 2008 Goldenberg et al.
January 29, 2008:459–65 Bezafibrate Therapy for Dyslipidemiaantly lower proportion of bezafibrate-allocated patients
ho had a more advanced heart failure or AP functional
lass (Table 2).
ardiac events during follow-up. During a mean
ollow-up period of 8.2 years, the combined end point of
ardiac death or nonfatal MI occurred in 276 of the 1,548
tudy patients allocated to bezafibrate (17.8%) and in 313 of
he 1,542 study patients allocated to placebo (20.3%; p 
.09). The components of the combined end point consisted
f, respectively, 125 (8.1%) and 144 (9.3%; p  0.21)
ardiac deaths and 177 (11.4%) and 203 (13.2%; p  0.14)
onfatal MIs.
Survival curves, describing the probability of the occur-
ence of cardiac death or nonfatal MI in the 2 treatment
roups (Fig. 2), demonstrated that after a total follow-up
eriod of 9 years, the cumulative probability of the com-
ined end point was 23.8% in the placebo group and 19.7%
n the bezafibrate group, representing a 17.6% reduction in
he rate of cardiac death or nonfatal MI (p  0.03).
Similar trends, showing nonsignificantly lower cumula-
ive event rates among patients allocated to the study
edication, were displayed for the separate occurrence of
ardiac death (22.6% reduction; p  0.16), nonfatal MI
20.0% reduction; p  0.10), and the need for coronary
rtery bypass grafting (12.6% reduction; p  0.08) during
ollow-up, whereas the rates of hospitalization for unstable
ngina, coronary angioplasty, and noncardiac mortality dur-
ng follow-up were similar in the 2 treatment groups (Table 3).
ultivariate analyses. We attempted to adjust for the
onfounding effect of unbalanced nonstudy LLD usage
uring the course of the trial on bezafibrate efficacy by using
alternative statistical approaches (Table 4).
In the first method (model 1), study patients who
eceived nonstudy LLDs during follow-up were censored
rom the analysis upon initiation of these medications.
Figure 1 Usage of Nonstudy
Lipid-Lowering Drugs by Treatment Group
Kaplan-Meier estimates of the rate of usage of nonstudy lipid-lowering
drugs during long-term follow-up by the original treatment allocation group.sing this methodology, bezafibrate therapy was shown
co be associated with a significant 17% reduction in the
isk of the combined end point of cardiac death or
onfatal MI compared with placebo therapy (p  0.03).
onsistent results were obtained when adjustment was
ade for time-dependent nonstudy LLD therapy in the
roportional hazards modeling of the combined end
oint (model 2). This analysis demonstrated an overall
5% risk reduction (p  0.06) with the study medication.
imilar to the results that were obtained in model 1,
nteraction-term analysis of model 2 showed a significant
8% reduction in the risk of cardiac death or nonfatal
I with bezafibrate without or before therapy with non-
tudy LLDs (p  0.03), whereas the effect of the study
edication was not significant (hazard ratio 1.05; p  0.85)
fter therapy with nonstudy LLDs was initiated during
ollow-up (Table 4).
When the combined end point of cardiac death or
onfatal MI was analyzed within the prespecified risk
ubgroups (Table 5), the benefit of bezafibrate therapy was
hown to be most prominent among patients with elevated
riglycerides (200 mg/dl; 37% risk reduction) and in-
reased BMI (27 kg/m2; 27% risk reduction) and signif-
cantly attenuated among patients with advanced heart
ailure or ischemic symptoms. No significant difference in
ezafibrate efficacy was shown in all other subgroups ana-
yzed (Table 5).
iscussion
n this extended follow-up study based on the intention-to-
reat principle, we compared the occurrence of cardiac death
r nonfatal MI in the 2 original treatment groups of the BIP
rial. We have shown that lipid-modifying therapy, consist-
ng of 400 mg bezafibrate per day, was associated with a
se of Nonstudyipid-Lowering Therapies During Follow-Up
Table 1 Use of NonstudyLipid-Lowering Therapies During Follow-Up
LLD Class
Bezafibrate
(n  1,548)
Placebo
(n  1,542) p Value
Double-blind phase, n (%)
Any LLD 169 (11) 273 (18) 0.001
Statins 114 (7) 166 (11) 0.001
Fibrates* 24 (2) 41 (3) 0.03
Colestipol† 58 (4) 111 (7) 0.001
Extended follow-up phase, n (%)
Any LLD 770 (50) 819 (53) 0.06
Statins 693 (51) 747 (55) 0.04
Fibrates 126 (9) 139 (10) 0.40
Colestipol† 4 (0.3) 12 (0.9) 0.045
At any time during follow-up, n (%)
Any LLD 812 (53) 871 (57) 0.02
Statins 721 (47) 778 (51) 0.03
Fibrates* 141 (9) 169 (11) 0.09
Colestipol† 59 (4) 112 (7) 0.001
Other than the study medication during the double-blind phase. †Colestipol was given according
o the study protocol as adjuvant therapy for patients with elevated low-density lipoprotein
holesterol.
LLD  lipid-lowering drug.
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Bezafibrate Therapy for Dyslipidemia January 29, 2008:459–65ignificant long-term 18% reduction in the risk of cardiac
eath or nonfatal MI among study subjects who were not
reated with concurrent nonstudy lipid-lowering therapies
uring follow-up or before nonrandomized treatment with
hese medications was initiated.
Baseline Clinical and Laboratory Characteristics
Table 2 Baseline Clinical and Laboratory Ch
Bezafibrate Group
Nonstudy LLD
No (n  812)
Clinical characteristics
Age, yrs 61  7
Male 665 (90)
Hypertension 220 (30)
DM 73 (10)
BMI, kg/m2 26.7  3.4
NYHA functional class 2 201 (28)
AP functional class 2 219 (30)
Prior MI 586 (80)
Prior angina 438 (60)
COPD 25 (3)
Medical therapy
Beta-blockers 254 (35)
Nitrates 407 (55)
Ca2-blockers 389 (53)
ACE inhibitors 95 (13)
Diuretics 115 (16)
Laboratory characteristics
Total cholesterol 209  17
HDL-C 35  6
LDL-C 146  16
Triglycerides 134  44
Fibrinogen 349  72
Values are presented as n (%) or mean  SD. *Yes indicates patients
extended follow-up period. †p  0.05 for the comparison of nonstudy
AP  angina pectoris; ACE  angiotensin-converting enzyme; BMI
diabetes mellitus; HDL-C  high-density lipoprotein cholesterol; LDL
myocardial infarction; NYHA  New York Heart Association.
Figure 2 Probability of Cardiac Death
or Nonfatal MI by Treatment Group
Kaplan-Meier estimates of the probability of the combined end point of cardiac
death or nonfatal myocardial infarction (MI) by the original treatment allocation
group.iThe VA-HIT (Veterans Affairs High-Density Lipopro-
ein Intervention Trial) (3) and the BIP trial (2) were 2
ajor randomized studies designed to determine the effect
f fibrate therapy on the risk of nonfatal MI and cardiac
ortality in CHD patients. Like gemfibrozil in the former
tudy, bezafibrate in the BIP trial significantly increased
DL-C levels (by 18%) and lowered triglycerides (by 21%).
owever, unlike the results of the VA-HIT study, which
emonstrated a significant 22% risk reduction with gemfi-
rozil (1,200 mg/day) during a median follow-up period of
.1 years, the reduction in the cumulative probability of the
rimary end point of the BIP trial after a similar mean
ollow-up period of 6.2 years was of smaller magnitude
7.3%; p  0.24).
Several possible explanations have been suggested to
ccount for the negative findings in the BIP trial. First,
DL-C levels were in a moderately high range at baseline
n the study, resulting in a relatively high frequency of
reatment with adjunctive “off-trial” LDL-C–lowering
herapies among placebo-allocated patients. The present
tudy shows that nonstudy LLDs, mainly statins, were
dministered to an increasingly greater proportion of
lacebo-allocated patients during the double-blind phase
reatment With Nonstudy LLDs
eristics by Treatment With Nonstudy LLDs
1,548) Placebo Group (n  1,542)
py Nonstudy LLD Therapy
(n  736) No (n  671) Yes* (n  871)
9  7† 61  7 60  7†
7 (92) 619 (92) 794 (91)
2 (32) 221 (33) 297 (34)
2 (10) 74 (11) 80 (9)
7  3.1 26.7  3.3 26.7  3.2
0 (22)† 168 (26) 197 (23)
5 (23)† 184 (27) 205 (23)
8 (78) 541 (81) 653 (75)†
9 (54)† 400 (60) 491 (56)†
1 (1)† 29 (4) 23 (3)
6 (40)† 238 (36) 371 (43)†
6 (48)† 349 (52) 432 (50)†
9 (48) 355 (53) 444 (51)
0 (11) 96 (14) 101 (12)
4 (13) 118 (18) 106 (12)†
5  18† 209  17 215  18†
4  5† 35  5 35  6
1  16† 146  16 137  17†
8  43 136  43 137
9  73 349  72 351 (77)
with nonstudy LLDs at any time during the course of the trial or the
erapy in each treatment group.
mass index; COPD  chronic obstructive pulmonary disease; DM 
w-density lipoprotein cholesterol; LLD  lipid-lowering drug; MI by T
aract
(n 
Thera
Yes*
5
74
26
8
26.
18
18
62
43
1
23
38
38
9
9
21
3
15
13
34
treated
LLD th
 bodyn the BIP trial, possibly attenuating the effect of the
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January 29, 2008:459–65 Bezafibrate Therapy for Dyslipidemiatudy medication on outcome toward the end of the trial.
econd, the BIP trial excluded several high-risk sub-
roups, including individuals with diabetes and higher
evels of blood glucose and patients with components of
he metabolic syndrome (6), in whom fibrate therapy has
een suggested to be more effective (7–10). Thus, possi-
ly owing to a higher use of off-study LLDs and less
revalent risk factors, the 5-year event rate in the placebo
roup in the BIP trial (13%) was relatively lower than in
he VA-HIT study (22%).
In the present study, we attempted to address these 2
otential limitations of the BIP trial. First, in the present
nalysis, either patients were censored upon initiation of
onstudy LLDs or further adjustment was made for
ime-dependent medical therapy with nonstudy LLDs
nd its interaction with bezafibrate therapy. These 2
tatistical approaches consistently demonstrated a signif-
cant long-term beneficial effect of bezafibrate therapy
efore additional off-trial lipid-lowering drugs were ad-
Cumulative Probability of Outcome Measures Du
Table 3 Cumulative Probability of Outcome
Bezafibrate
(n  1,548)
Combined end point (cardiac death
or nonfatal MI)
19.7%
Cardiac death 9.6%
Nonfatal MI 12.3%
Mortality
All-cause 18.2%
SCD 4.7%
Non-SCD 15.4%
Noncardiac 9.7%
Other
Unstable angina 9.7%
CABG 15.3%
PTCA 9.7%
CVA† 8.6%
*Patients were censored from the analysis upon initiation of nonstud
CABG  coronary artery bypass grafting; CVA  cerebrovascular
angioplasty; SCD  sudden cardiac death.
Bezafibrate- Versus Placebo-Allocated Patients’Cardiac D ath or Nonf tal Myocardial InfarctionP iod: Ov rall Effect
Table 4
Bezafibrate- Versus Placebo-Allocat
Cardiac Death or Nonfatal Myocard
Period: Overall Effect
Model 1: patients censored upon initiation of nonstudy LLD
Bezafibrate versus placebo (n  3,090)
Model 2: adjusted for time-dependent nonstudy LLD therap
Bezafibrate versus placebo (n  3,090)
Bezafibrate versus placebo before or without nonstudy LL
Bezafibrate versus placebo after initiation of nonstudy LL
*Findings were adjusted for the following covariates: age, prior myoca
at the time of inclusion in the study, chronic obstructive pulmonary di
propensity score model that included treatment group, time-depende
LLDs; a treatment group time-dependent LLD therapy interaction ter
and after initiation of nonstudy LLD therapy; similar findings were ob
adjusted for treatment group, time-dependent nonstudy LLD therapy
interaction p  0.25.
CI  confidence interval; HR  hazard ratio; LLD  lipid-lowering drug.inistered to an unequal proportion of patients in the 2
reatment groups. Second, the continued follow-up for
atal and nonfatal cardiac events, after discontinuation of
he study medication, resulted in a cumulative event rate
f 24% in the BIP trial over a mean follow-up period of
.2 years, which is similar to the 22% event rate reported
fter 5 years of follow-up in the VA-HIT study (3).
The present findings are consistent with earlier studies
hat have shown that the benefit of fibrate therapy is more
rominent among patients with components of the meta-
olic syndrome (7–10). However, the mechanisms underly-
ng the findings regarding the lack of bezafibrate benefit
mong patients with symptoms suggestive of advanced
schemia and heart failure are not clear. Unbalanced admin-
stration of nonstudy LLDs occurred more frequently
mong study patients with these risk factors. Thus, a higher
ate of cardiac events may have persisted in the subset of
ezafibrate-allocated patients with symptoms of advanced
eart failure and AP who received a lower proportion of
Extended Follow-Up*
ures During Extended Follow-Up*
Placebo
(n  1,542) Rate Reduction p Value
23.9% 17.6% 0.03
12.4% 22.6% 0.16
15.4% 20.0% 0.10
21.0% 13.3% 0.40
5.1% 7.8% 0.47
17.1% 9.9% 0.59
9.9% 2.0% 0.73
9.9% 2.0% 0.32
17.5% 12.6% 0.08
10.0% 3.0% 0.80
10.4% 17.3% 0.44
wering therapies. †Defined as an ischemic or nonischemic event.
t; MI  myocardial infarction; PTCA  percutaneous transluminal
for the Combined End Point ofng the Extended Follow-Up
tients’ Risk for the Combined End Point of
farction During the Extended Follow-Up
HR 95% CI p Value
0.83 0.70–0.99 0.03
0.85 0.71–1.01 0.06
apy‡ 0.82 0.68–0.98 0.03
apy‡ 1.05 0.64–1.71 0.85
farction, history of diabetes mellitus, reported hypertension, smoking
nd angina pectoris functional class. †Findings were obtained from a
tudy LLD therapy, and a propensity score for therapy with nonstudy
dded to the model to assess the effect of the study medication before
using multivariate Cox proportional hazards regression models that
e covariates listed for model 1. ‡Treatment group  nonstudy LLDring
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Bezafibrate Therapy for Dyslipidemia January 29, 2008:459–65onstudy LLDs (and possibly other cardioprotective medica-
ions) than the respective patients in the placebo group (Table
). Future prospective randomized trials are needed to evaluate
ezafibrate efficacy in risk subgroups of CHD patients.
tudy limitations. The present study is limited by the post
oc nature of the analysis. However, we believe that the
onsistent data collection regarding medical management and
ardiac events after the double-blind phase of the trial allowed
 comprehensive comparison of the clinical course of the
riginal allocation groups over an extended follow-up period.
It should also be noted that the significant long-term
ffects of bezafibrate therapy were observed only after
atients were censored from this analysis upon initiation of
onstudy LLDs or when interaction-term analysis was used
o assess bezafibrate efficacy before other lipid-lowering
herapies were administered. Therefore, further studies are
eeded to determine the incremental benefit of fibrates in
he current era of widespread statin use for secondary
revention in CHD patients.
onclusions
ata from major clinical trials support treatment of CHD
atients with low HDL-C (11). The present findings suggest
ezafibrate- Versus Placebo-Allocated Patients’ Risk for the Combiath or Nonfatal Myocardial Infarction During the Extended Follow
Table 5 Bezafibrate- Versus Placebo-Allocated Patients’ Risk foDeath or Nonfatal Myocardial Infarction During the Ext
Model 1: Patients Censo
Nonstudy
HR (95% CI)
Diabetes mellitus
Yes (n  309) 0.83 (0.49–1.40)
No (n  2,779) 0.84 (0.69–1.00)
Prior myocardial infarction
Yes (n  679) 0.83 (0.68–1.00)
No (n  2,408) 0.87 (0.57–1.32)
Body mass index
27 kg/m2 (n  1,292) 0.74 (0.57–0.96)
27 kg/m2 (n  1,796) 0.92 (0.72–1.16)
Triglycerides
200 mg/dl (n  459) 0.63 (0.40–0.98)
200 mg/dl (n  2,612) 0.87 (0.72–1.06)
High-density lipoprotein cholesterol
40 mg/dl (n  2,510) 0.82 (0.68–0.99)
40 mg/dl (n  566) 0.91 (0.60–1.39)
New York Heart Association functional class
2 (n  746) 1.27 (0.90–1.79)
2 (n  2,299) 0.72 (0.59–0.88)
Angina pectoris functional class
2 (n  793) 1.30 (0.94–1.80)
2 (n  2,297) 0.70 (0.57–0.86)
Findings were adjusted for the following covariates: age, prior myocardial infarction, history of di
ulmonary disease, and angina pectoris functional class. †Findings were obtained from a propens
core for therapy with nonstudy LLDs; similar findings were obtained using multivariate Cox pro
ovariates listed for model 1.
Abbreviations as in Table 4.hat the HDL-C–raising effect of bezafibrate therapy in CHDatients with dyslipidemia is associated with a significant
ong-term reduction in major cardiovascular events that ex-
ends beyond the period of active treatment with the drug.
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